Semaglutide, marketed under brand names including Ozempic, Wegovy, and Rybelsus, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes management and chronic weight management
Red flags to watch out for Wegovy (semaglutide) can cause mild and temporary gastrointestinal side effects such as nausea, abdominal discomfort, bloating, stomach ache, diarrhea, constipation, and vomiting
accepted April 7, 2025
This means the higher the dose, the more weight loss will be seen for most patients if they are responsive to the medication in general
Ozempic works in part by delaying gastric emptying , the movement of stomach contents into the intestines
A survey study of 59 women with HS found that the majority had not received information from their physician on how their disease and medications could impact pregnancy outcomes [5]